BridgeBio price target raised to $81 from $73 at Oppenheimer

Oppenheimer raised the firm’s price target on BridgeBio (BBIO) to $81 from $73 and keeps an Outperform rating on the shares. The firm notes U.S. Attruby revenue of $108M surpassed its/Street’s expectations of $106/95M. Ex-U.S. sales contributed $4.3M in royalty revenue. Oppenheimer says there could be some slight adherence headwinds developing over time as patients may come off drug without noticing benefit, though this is built into its $1B 2026 Attruby sales expectations. Shares may take a breather after this week’s +13% move, but the firm remains Outperform-rated and would be buying into infigratinib’s early 2026’s readout.